Effect of Siddha Varmam therapy for the treatment of shoulder pain and disability.

A single center randomized parallel group clinical trial to compare the efficacy of Siddha Varmam Therapy and Thailam Application (SVT) versus Thailam Application (TA) in terms of pain and disability in the treatment of Kumbavatham (Adhesive capsulitis)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/08/027350

Enrollment

200

Registered

2020-08-24

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M750- Adhesive capsulitis of shoulder

Interventions

Intervention1: Siddha Varmam Therapy and Thailam application: The group will be given Varmam therapy and Vatha kesari thailam application. Treatment duration:3 days in a week for 6 weeks, ie 18 visits

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients with shoulder pain > 70% SPADI lasting for more than a month and range of motion limited at least 25% in one or more directions measured using Goniometer. 2.Duration of complaints > 3 months

Exclusion criteria

Exclusion criteria: 1.History of Rotator tear, traumatic history, history of surgery in shoulder joint in the preceding 1 year, patients who underwent Varmam treatment/any other external treatment for kumbavatham within last three months prior to enrolment, history of fracture in clavicle, humerus, scapula and bones of upper limbs, osteoarthritis shoulder, Cervical neuropathy, paralysis, neurological disorder, shockwave or injection therapy in shoulder joint, Ischemic Heart Disease, rheumatoid arthritis, dislocation, osteoporosis, lifting heavy weight in routine life, pregnancy, lactation. 2.Intervention model: parallel assignment. 3.Arms: 2 (Experimental arm-2) 4.Experimental arm 1: Thailam Application. 5.Experimental arm 2: Varmam + Thailam Application.

Design outcomes

Primary

Measure	Time frame
•Reduction in shoulder pain and improvement in range of movements of shoulder joint. It is assessed by Shoulder Pain and Disability Index – SPADI.Timepoint: Screening, At the time of recruitment, End of the trial period. Time point: 6 weeks	—

Secondary

Measure	Time frame
• Quality of life of trial participants. It will be assessed by Quality of life questionnaire. (SF-36 questionnaire). • End point classification: SPADI, SF-36, Safety Parameters. • Time schedule of enrolment: 18 months. Project duration: 3 years. • Treatment duration: 3 days in a week on alternate days for 6 weeks, ie 18visits Timepoint: At the time of recruitment and at the end of the trial period. Time point: 6 weeks	—

Measure

Time frame

• Quality of life of trial participants. It will be assessed by Quality of life questionnaire. (SF-36 questionnaire). • End point classification: SPADI, SF-36, Safety Parameters. • Time schedule of enrolment: 18 months. Project duration: 3 years. • Treatment duration: 3 days in a week on alternate days for 6 weeks, ie 18visits Timepoint: At the time of recruitment and at the end of the trial period. Time point: 6 weeks

—

Countries

India

Contacts

Public ContactMEENA R

Siddha Central Research Institute

meenaprakashphd@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026